Precision BioSciences Announces Dosing of First Patient in Off-The-Shelf CAR T Cell Therapy Phase 1/2a Clinical Trial

First NHL patient treated with allogeneic CAR T in US-based trial DURHAM, North Carolina, April 17, 2019 – Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company...


Precision BioSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

DURHAM, North Carolina, April 1, 2019 – Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome...


Precision BioSciences Announces Pricing of Initial Public Offering

DURHAM, North Carolina, USA, March 28, 2019 – Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS...


Raymond Schinazi Joins Precision BioSciences Board of Directors

DURHAM, North Carolina, USA, March 14, 2019 –Precision BioSciences (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing...


Precision BioSciences Enters Into Private Convertible Note Financing

DURHAM, North Carolina, USA, March 9, 2019 – Precision BioSciences (“Precision” or the “Company”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS...


Elo Life Systems Announces a Collaboration With Ashland Subsidiary Avoca to Scale a Sustainable, Key Input for Fragrances

DURHAM, NORTH CAROLINA – February 25, 2019 – Elo Life Systems Inc. announced today a collaboration with Avoca LLC, a subsidiary of the specialty chemicals company Ashland, that is focused on...


Precision BioSciences Announces Formation of Scientific Advisory Board With Anderson, Kantarjian, Schinazi and Turtle

DURHAM, North Carolina, USA, January 16, 2019 – Precision BioSciences today announced the formation of its Scientific Advisory Board (SAB) with four key appointments: Kenneth C. Anderson, MD,...


Precision BioSciences Appoints Rare Disease Executive Shalini Sharp to Its Board of Directors

DURHAM, North Carolina, USA, December 19, 2018 – Precision BioSciences, a genome editing company dedicated to improving life, announced today that industry veteran Shalini Sharp has joined the...


Precision BioSciences and Durham STEM Students Lead Launch of First Genome Editing Experiment Into Space

CAPE CANAVERAL, FL, USA, December 6th, 2018 – Precision BioSciences today announced that the world’s first genome editing experiment in space has been launched aboard a SpaceX Dragon cargo...


Science Article About the Quest to Cure HBV Brings Context to Precision BioSciences Collaboration With Gilead

Precision BioSciences is pleased to be part of this important feature story from Science Magazine: Forgotten No More – A long-overlooked scourge of millions, hepatitis B is in the crosshairs...


Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy

DURHAM, North Carolina, USA, November 27, 2018 – Precision BioSciences and Servier today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND)...


Precision BioSciences Receives the 2018 SEBIO Venture Funding Award

DURHAM, North Carolina, USA, November 15, 2018 – Precision BioSciences announced today that it has been recognized as the recipient of the 2018 Southeast BIO (SEBIO) Venture Funding Award. Abid...


Precision BioSciences and MaxCyte Enter Into Clinical and Commercial License Agreement

Precision BioSciences is pleased to be working with MaxCyte. Read more about our clinical and commercial license agreement to use the MaxCyte electroporation system for non-viral delivery of genome...


Elo Life Systems Launches Australian Subsidiary in Queensland

RESEARCH TRIANGLE PARK, North Carolina, USA and BRISBANE, Australia, November 5, 2018 – Elo Life Systems has opened a new Australian location at the Queensland University of Technology (QUT),...


Mario G. Pennisi, Australian Life Sciences Industry Leader, Joins Elo-Australia as Resident Director

RESEARCH TRIANGLE PARK, North Carolina, USA and BRISBANE, Australia, October 10, 2018 – Elo Life Systems Inc. announced today that Mario G. Pennisi joined Elo Life Systems as a Resident...